Novavax Inc. filings document formal disclosures for a Nasdaq-listed biotechnology company focused on vaccine products, Matrix-M adjuvant technology and partnership-driven development. Recent 8-K reports record operating results, preliminary financial information, licensing arrangements for Matrix-M, Nuvaxovid marketing-authorization transfers, and facility-related agreements.
Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and governance procedures. The filings also identify Novavax common stock, par value $0.01 per share, as listed on The Nasdaq Global Select Market under NVAX.
Novavax Executive Vice President, CFO and Treasurer James Patrick Kelly reported an amended insider filing reflecting a grant of 194,000 non‑statutory stock options awarded on March 2, 2026. One-quarter of the options vest on the first anniversary of that date, with the remaining three-quarters vesting in equal monthly installments over the following three years, all conditioned on continued employment. The amendment only updates the exercise price previously reported; all other details remain the same, and the options are held directly.
NOVAVAX INC executive vice president of research and development Ruxandra Draghia-Akli reported an amended insider filing related to a previously disclosed stock option grant. On March 2, 2026, she was granted a non-statutory stock option covering 139,500 shares, held directly.
According to the filing, this Form 4/A was filed solely to amend the exercise price previously reported; all other information from the original March 5, 2026 Form 4 remains unchanged. One quarter of the option vests on the first anniversary of March 2, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued employment.
Novavax Inc. executive Mark J. Casey reported an amended stock option grant. The Form 4/A updates only the exercise price originally reported for a non-statutory stock option covering 152,000 shares that was granted on March 2, 2026; all other details from the earlier filing remain the same.
The option was granted at no cash cost per option share and is held directly. One quarter of the 152,000 option shares vests on the first anniversary of March 2, 2026, and the remaining three quarters vest in equal monthly installments over the following three years, subject to continued employment.
NOVAVAX INC director and President and CEO John C. Jacobs reported a grant of 551,500 non-statutory stock options on March 2, 2026. This Form 4/A solely amends the exercise price originally reported in the prior Form 4; all other details are unchanged.
One quarter of the option vests on the first anniversary of March 2, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued employment.
Novavax executive Elaine O’Hara, EVP and Chief Strategy Officer, filed an amended Form 4 to correct the exercise price previously reported for a 2026 non-statutory stock option grant covering 177,500 shares awarded on March 2, 2026. All other details from the earlier filing remain unchanged.
Under this option, one-quarter of the shares vest on the first anniversary of March 2, 2026, and the remaining three-quarters vest in equal monthly installments over the following three years, subject to her continued employment with the company.
Novavax EVP, CFO and Treasurer James Patrick Kelly reported equity award activity. On March 3, 2026, he acquired 43,167 shares of common stock through the exercise and vesting of restricted stock units at no cost. On the same date, 20,850 shares of common stock were withheld by the company at $9.49 per share to cover tax obligations, leaving him with 124,280 directly held common shares.
Novavax Inc. President and CEO John C. Jacobs reported equity award activity. He exercised 150,167 Restricted Stock Units into an equal number of common shares at $0.0000 per share through a derivative conversion, then 69,288 common shares were withheld at $9.49 per share to cover tax obligations, leaving him with 225,680 common shares held directly.
Novavax executive Elaine O'Hara reported equity compensation activity involving restricted stock units and common shares. On March 3, 2026, she exercised or converted 56,334 restricted stock units, resulting in the acquisition of 56,334 shares of Novavax common stock at a stated price of $0.00 per share.
To cover tax withholding on this RSU vesting, 22,429 shares of common stock were withheld by the company at $9.49 per share, described as a tax-withholding disposition rather than an open-market sale. Following these transactions, O'Hara directly owned 134,642 shares of Novavax common stock. Footnotes state that one-third of the RSUs from this grant vest on each of the first three anniversaries of March 3, 2025, subject to continued employment.
Novavax EVP and Chief Legal Officer Mark J. Casey reported equity compensation activity involving restricted stock units and common stock. On March 3, 2026, 4,000 restricted stock units were converted and 37,500 shares of common stock were acquired through an exercise or conversion of derivative securities at a stated price of $0.00 per share.
In a related move, 11,378 shares of common stock were withheld at $9.49 per share to satisfy tax withholding obligations tied to the RSU vesting, leaving 90,067 shares of common stock held directly after these transactions. A footnote explains that one-third of the RSUs under the company’s 2015 Stock Incentive Plan vest on each of the first three anniversaries of March 3, 2025, subject to continued employment.
Novavax EVP of R&D Ruxandra Draghia-Akli reported new equity awards and related share movements. On March 2, 2026, she received 93,000 Restricted Stock Units and a non-statutory stock option for 139,500 shares at $9.09 per share, each vesting over several years subject to continued employment.
On March 3, 2026, 26,667 RSUs were converted into common stock, with the same number of RSUs disposed back to the company. To cover tax withholding on RSU vesting, 11,313 shares of common stock at $9.49 per share were withheld, leaving her with 23,563 common shares held directly.